
Page#1
ZOETIS INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
Year Ended December 31,
(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA) 2017 2016 2015
Revenue $ 5,307 $ 4,888 $ 4,765
Costs and expenses:
Cost of sales(a) 1,775 1,666 1,738
Selling, general and administrative expenses(a) 1,334 1,364 1,532
Research and development expenses(a) 382 376 364
Amortization of intangible assets 91 85 61
Restructuring charges and certain acquisition-related costs 19 5 320
Interest expense, net of capitalized interest 175 166 124
Other (income)/deductions––net 6 (2) 81
Income before provision for taxes on income 1,525 1,228 545
Provision for taxes on income 663 409 206
Net income before allocation to noncontrolling interests 862 819 339
  Less: Net loss attributable to noncontrolling interests (2) (2) —
Net income attributable to Zoetis $ 864 $ 821 $ 339
Earnings per share attributable to Zoetis Inc. stockholders:
 Basic $ 1.76 $ 1.66 $ 0.68
 Diluted $ 1.75 $ 1.65 $ 0.68
Weighted-average common shares outstanding:
 Basic 489.918 495.715 499.707
 Diluted 493.161 498.225 502.019
Dividends declared per common share $ 0.441 $ 0.390 $ 0.344
(a) Exclusive of amortization of intangible assets, except as disclosed in Note 3. Significant Accounting Policies—Amortization of Intangible Assets, Depreciation and 
Certain Long-Lived Assets. 
See Notes to Consolidated Financial Statements, which are an integral part of these statements.
61 |
Page#2
ZOETIS INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS 
December 31, December 31,
(MILLIONS OF DOLLARS, EXCEPT PER SHARE DATA) 2017 2016
Assets
Cash and cash equivalents(a) $ 1,564 $ 727
Accounts receivable, less allowance for doubtful accounts of $25 in 2017 and $30 in 2016 998 913
Inventories 1,427 1,502
Other current assets 228 248
Total current assets 4,217 3,390
Property, plant and equipment, less accumulated depreciation of $1,471 in 2017 and $1,358 in 2016 1,435 1,381
Goodwill 1,510 1,481
Identifiable intangible assets, less accumulated amortization 1,269 1,228
Noncurrent deferred tax assets 80 96
Other noncurrent assets 75 73
Total assets $ 8,586 $ 7,649
Liabilities and Equity
Accounts payable $ 261 $ 265
Dividends payable 61 52
Accrued expenses 432 464
Accrued compensation and related items 236 224
Income taxes payable 60 71
Other current liabilities 44 41
Total current liabilities 1,094 1,117
Long-term debt, net of discount and issuance costs 4,953 4,468
Noncurrent deferred tax liabilities 380 244
Other taxes payable 172 73
Other noncurrent liabilities 201 248
Total liabilities 6,800 6,150
Commitments and contingencies (Note 17)
Stockholders' equity:
Preferred stock, $0.01 par value; 1,000,000,000 authorized, none issued — —
Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued;  
486,130,461 and 492,855,297 shares outstanding at December 31, 2017 and 2016, respectively 5 5
Treasury stock, at cost, 15,760,782 and 9,035,946 shares of common stock at December 31, 2017 and 2016,
respectively (852) (421)
Additional paid-in capital 1,013 1,024
Retained earnings 2,109 1,477
Accumulated other comprehensive loss (505) (598)
Total Zoetis Inc. equity 1,770 1,487
Equity attributable to noncontrolling interests 16 12
Total equity 1,786 1,499
Total liabilities and equity $ 8,586 $ 7,649
(a) As of December 31, 2017, includes $6 million of restricted cash.
See Notes to Consolidated Financial Statements, which are an integral part of these statements.
63 |
Page#3
ZOETIS INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
Year Ended December 31,
(MILLIONS OF DOLLARS) 2017 2016 2015
Operating Activities
Net income before allocation to noncontrolling interests $ 862 $ 819 $ 339
Adjustments to reconcile net income before noncontrolling interests to net cash
provided by operating activities:
Depreciation and amortization expense 242 240 199
Share-based compensation expense 44 37 43
Restructuring 19 5 203
Asset write-offs and asset impairments 3 5 60
Loss/(gain) on sales of assets 11 (26) —
Provision for losses on inventory 54 105 94
Deferred taxes 127 (55) (85)
Foreign currency loss related to Venezuela Revaluation, excluding impact on cash — — 6
Employee benefit plan contribution from Pfizer Inc. 3 3 3
Other non-cash adjustments 10 19 10
Other changes in assets and liabilities, net of acquisitions and divestitures and transfers with Pfizer Inc.
Accounts receivable (50) 15 (58)
Inventories 19 (101) (262)
Other assets (16) (50) (9)
Accounts payable (10) (28) 17
Other liabilities (57) (295) 70
Other tax accounts, net 85 20 34
Net cash provided by operating activities 1,346 713 664
Investing Activities
Capital expenditures (224) (216) (224)
Acquisitions (82) (88) (883)
Net proceeds from sales of assets 37 90 2
Other investing activities (1) — (10)
Net cash used in investing activities (270) (214) (1,115)
Financing Activities
Decrease in short-term borrowings, net — (5) (2)
Principal payments on long-term debt (750) (400) —
Proceeds from issuance of long-term debt—senior notes, net of discount and fees 1,231 — 1,236
Payment of contingent consideration related to previously acquired assets (7) (32) —
Share-based compensation-related proceeds, net of taxes paid on withholding shares and excess tax benefits(a) 24 25 11
Purchases of treasury stock(b) (500) (300) (203)
Cash dividends paid (206) (188) (168)
Cash paid to settle Pharmaq debt — — (119)
Acquisition of noncontrolling interest (43) — —
Payment of debt issuance costs — (3) —
Net cash (used in)/provided by financing activities (251) (903) 755
Effect of exchange-rate changes on cash and cash equivalents 12 (23) (32)
Net increase/(decrease) in cash and cash equivalents 837 (427) 272
Cash and cash equivalents at beginning of period 727 1,154 882
Cash and cash equivalents at end of period $ 1,564 $ 727 $ 1,154
See Notes to Consolidated Financial Statements, which are an integral part of these statements.
65 |
Page#4
Supplemental cash flow information
Cash paid during the period for:
 Income taxes $ 455 $ 408 $ 224
 Interest, net of capitalized interest 167 165 117
Non-cash transactions:
 Capital expenditures $ 5 8 11
 Contingent purchase price consideration(c) 29 27 23
 Dividends declared, not paid 61 52 47
(a) Effective 2016, excess tax benefits are reflected within operating activities. See Note 3. Significant Accounting Policies for additional information. 
(b) Reflects the acquisition of treasury shares in connection with the share repurchase program. For additional information, see Note 15. Stockholders' Equity.
(c) For 2016, relates primarily to the non-cash portion of the acquisition of a livestock business in South America and a veterinary diagnostics business in Denmark. 
For 2015, relates primarily to the non-cash portion of the acquisition of certain assets of Abbott Animal Health. 
See Notes to Consolidated Financial Statements, which are an integral part of these statements.
66 |